Pain and I are well acquainted. I would not go so far as to say we are friends, but we do see each other every day. It isn’t always first thing in the morning; sometimes it’s midafternoon, right after I think to myself, “Wow, pain hasn’t shown up at my doorstep today.” Or it arrives…
ACTRIMS 2026: Bazedoxifene fails to boost myelin repair in women with MS
Bazedoxifene, a medication that alters the activity of the sex hormone estrogen, was safe and well-tolerated but did not promote myelin repair in women with multiple sclerosis (MS) in a Phase 2 clinical trial. The findings come from the ReWRAP study (NCT04002934) and were presented last week at the Americas Committee for Treatment and Research…
ACTRIMS 2026: New study questions whether EBV precedes every MS case
A Canadian study is challenging the growing belief that previous infection with the Epstein-Barr virus (EBV) is necessary for multiple sclerosis (MS) to develop. The findings suggest the virus may not precede every MS case. Using public health insurance claims data, the researchers found a small group of people whose MS-related diagnostic claims appeared before…
Cuando la fortaleza dificulta acercarse a los demás
La fortaleza y la autosuficiencia suelen considerarse como una medalla de honor. Para muchas personas, especialmente aquellas que viven con enfermedades crónicas o incertidumbre constante, la fortaleza se vuelve sinónimo de supervivencia. Nos permite superar días difíciles, pero a menudo … Continue reading → Source: blog.mymsaa.org
When Strength Makes It Hard to Let Others In
Strength and self-reliance are often worn like a badge of honor. For many people, especially those living with chronic illness or ongoing uncertainty, strength becomes synonymous with survival. It allows us to push through difficult days, but it often comes … Continue reading → Source: blog.mymsaa.org
Know one know them all…or Not CD20-antibodies
Tweet Loss of circulating antibody as a result of continuous B cell depletion is a risk factor for infection. The battle grounds to distinguish between the different anti-CD20 has been centred on loss of IgG. It has been suggested that ofatumumab does not induce as much loss of antibody as ocrelizumab. Indeed if you look…
Auto Draft
The post Auto Draft appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
ACTRIMS 2026: Mediterranean diet may help slow disability worsening in MS
Better adherence to a Mediterranean-like diet may help prevent disability worsening in people with early multiple sclerosis (MS), in part by slowing biological aging, according to data from a new study. The findings suggest that diet, biological age, and disability are closely connected and that lifestyle changes could potentially influence long-term disease outcomes. “Biological aging…
ACTRIMS 2026: Tolebrutinib misses main goal in PPMS Phase 3 PERSEUS trial
The investigational BTK inhibitor tolebrutinib did not lower the risk of confirmed disability progression compared with placebo in people with primary progressive multiple sclerosis (PPMS), failing to meet the main goal and several key secondary goals of the Phase 3 PERSEUS trial. It did, however, show signs of benefit on MRI scans, including fewer new…
Was the EBV mimicry Idea based on Quicksand?
Tweet A couple of years ago we were awakened to the prospect of EBV being the cause of multiple sclerosis, at least part of the causal route. It was based on two papers one that it was shown that people who develop MS were infected with Epstein Bar Virus before, maybe years, they got MS….